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Abstract: Data on zidovudine pharmacokinetics in children dosed using 
World Health Organization weight bands are limited. About 45 HIV-
infected, Ugandan children, 3.4 (2.6–6.2) years, had intensive pharma-
cokinetic sampling. Geometric mean zidovudine AUC
0–12h
 was 3.0 h.mg/L, 
which is higher than previously observed in adults, and was independently 
higher in those receiving higher doses, younger and underweight children. 
Higher exposure was also marginally associated with lower hemoglobin.
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Current World Health Organization (WHO) 2010 guidelines for the treatment of HIV-infected children recommend 2 
nucleoside reverse transcriptase inhibitors as part of first-line com-
bination antiretroviral therapy (ART).1 For infants/children, the 
preferred nucleoside reverse transcriptase inhibitor backbone is 
twice-daily lamivudine + zidovudine, which is effective, inexpen-
sive and available as fixed-dose combination scored adult tablets 
(Combivir, GlaxoSmithKline, London, United Kingdom),2 which 
can be split for pediatric dosing, or as generic dual or triple (with 
nevirapine) pediatric FDCs. However, although studies have inves-
tigated the pharmacokinetics of the current lamivudine doses,3 
surprisingly most zidovudine pharmacokinetic data are based on 
old 6–8 hourly and/or higher dosing.4,5 Data on zidovudine phar-
macokinetics and pharmacodynamics at currently recommended 
lower/less frequent doses in children remain sparse, particularly 
in African children.6 Pharmacokinetic-pharmacodynamic stud-
ies are particularly important as anemia is a common, plausibly 
 dose-related, toxicity.7,8 
As ~90% HIV-infected children needing ART are in Africa, 
we investigated zidovudine exposure in Ugandan, HIV-infected 
children receiving WHO-recommended  twice-daily, weight band-
based dosing (not studied to date).
METHODS
ARROW was an open randomized trial comparing moni-
toring and first-line ART strategies in HIV-infected Ugandan/
Zimbabwean children eligible for and initiating ART.9 Allocation 
to  zidovudine-containing regimens or not was part of the first-line 
ART strategy randomization.9 Once stable on ART (>24 weeks 
after initiation) children from 2 Ugandan ARROW centers (Joint 
Clinical Research Centre, Kampala and Paediatric Infectious Dis-
ease Centre, Mulago, Kampala) were approached for additional 
consent to participate in 2 intensive crossover pharmacokinetic 
substudies. The first compared twice- versus once-daily lamivudine 
and abacavir in children 3–12 years of age, before and 4 weeks after 
move to once-daily dosing, 36 weeks after ART initiation.3 All chil-
dren were taking efavirenz; some were also taking zidovudine as a 
4th drug at the first (36-week) pharmacokinetic sampling day. The 
second substudy compared twice-daily zidovudine, lamivudine and 
abacavir as syrups versus tablets in children 1–4 years of age, at and 
4 weeks after moving from syrups to tablets6 [median interquartile 
range (IQR) 56 (40–70) weeks on ART].
This analysis included all available zidovudine pharmacoki-
netic data from both substudies. Children on concomitant medica-
tion which could interfere with ART or who had illnesses that could 
influence ART pharmacokinetics were excluded, as were children 
who reported missing any ART dose in the previous 3 days. All 
caretakers provided fully informed written consent. The pharma-
cokinetic substudies were approved by the Ethics Committee from 
each centre.
Zidovudine was dosed twice daily as syrups or halved or whole 
300 mg solid formulation and scored fixed-dose combination tablets 
(provided by GlaxoSmithKline; Table, Supplemental Digital Content, 
http://links.lww.com/INF/B733). Doses followed WHO 2006 recom-
mendations, except that children weighing 12–15 kg received 240 mg 
zidovudine syrup daily instead of 220 mg, children weighing 20–21 kg 
on lamivudine/zidovudine FDCs received 300 mg zidovudine rather 
than 450 mg and children 21 to <25 kg received 450 mg zidovudine 
to harmonize with the lamivudine weight band. Blood samples of 
1.5 mL were taken at t = 0, 1, 2, 4, 6, 8 and 12 hours after observed 
ART intake. Breakfast (mostly milk/milky tea with samosas/bread/
chapati) was provided 2 hours post morning dose. Plasma concentra-
tions were assayed by a validated high-performance liquid chromatog-
raphy-tandem mass spectrometry method,10 with lower limit of quan-
tification 0.0025 mg/L, by Worldwide Bioanalysis, GlaxoSmithKline, 
Research Triangle Park, North Carolina. Zidovudine pharmacokinetic 
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parameters [C
12h
, C
max
, AUC
0–12h
, t½, oral clearance (CLF)] were cal-
culated using WinNonlin version 5.2 (Pharsight Corporation, Moun-
tain View, CA). To explore predictors of zidovudine exposure using 
WHO weight band dosing, associations between zidovudine AUC
0–12h
 
and sex, age, dose (mg/m2), weight- and height-for-age and formula-
tion were investigated using multivariable mixed models including a 
child-level random effect (STATA version 11.1, STATA Corp, Col-
lege Station, TX).
RESULTS
Zidovudine pharmacokinetic data were included from 45 
children (17 (38%) male). Twenty-eight (62%) children 1–4 years 
of age had 2 pharmacokinetic profiles (1 each on syrup and tablets) 
and 17 (38%) children 3–12 years of age had 1 profile on tablets. 
One child had C
0h
 > 3·C
12h
 and was excluded, leaving 72 pharma-
cokinetic profiles available for analyses. Median (IQR) age and 
weight at the first pharmacokinetic day were 3.4 (2.6–6.2) years and 
12.6 (12.3–18.0) kg, respectively. Median (IQR)  weight-for-age 
and height-for-age z-scores were −1.09 (−1.62 to −0.56) and −1.85 
(−2.68 to −1.20), indicating moderate wasting and stunting. Of the 
72 evaluable profiles, median (IQR) zidovudine morning and total 
daily doses were 242 (218–278) and 466 (432–546) mg/m2, respec-
tively [10 (9.4–12.2) and 20 (18.5–23.9) mg/kg respectively]. Eight 
(11%), 20 (27%) and 36 (50%) profiles were from children on 
100 mg syrup, 120 mg syrup and 150 mg lamivudine/zidovudine 
fixed-dose combination tablets twice daily, respectively; and 8 
(11%) were on 300 mg morning and 150 mg evening tablets.
The geometric mean (GM; 95% confidence interval) 
AUC
0–12h
, C
max,
 C
12h
, t½ and CLF, and CLF/kg was 3.0 (2.7–3.3) h.mg/L, 
1.8 (1.6–1.9) mg/L and 0.009 (0.007–0.010) mg/L, 2.3 (2.1–2.5) h, 
48.6 (43.1–54.6) L/h and 3.5 (3.2–3.8) L/h.kg, respectively (Fig. 1A) 
with CV% of 40%, 42%, 70%, 18%, 54% and 44%, respectively. 
Zidovudine AUC
0–12h
 was 27–150% higher than previously reported 
in adults.2,11 GM C
max
 were 1.84 mg/L and 1.58 mg/L in children less 
than and greater than 4 years (P = 0.12, rank sum), respectively.
In multivariable models, higher zidovudine exposure 
(AUC
0–12h
) was independently associated with higher dose, younger 
age and lower weight-for-age, with the latter 2 factors indepen-
dently associated with CLF. AUC
0–12h
 was 0.43 h.mg/L higher for 
every 50 mg/m2 higher zidovudine dose (95% confidence interval: 
FIGURE 1. Mean zidovudine concentrations, exposure, age and hemoglobin at pharmacokinetic sampling. A) Mean 
zidovudine plasma concentrations. B) Relationship between zidovudine exposure [area under the concentration–time curve 
0–12 hours postdose (AUC0–12h)] and age (years) at pharmacokinetic sampling. C) Relationship between zidovudine clearance 
(CLF/kg) and age (years) at pharmacokinetic sampling. D) Relationship between hemoglobin and zidovudine exposure 
[area under the concentration–time curve 0–12 hours postdose (AUC0–12h)] at pharmacokinetic sampling. Note: In panel A), 
children receiving 450 mg daily received 300 mg zidovudine in the morning and are included in this group. In panel B), fitted 
effect of age is shown for a child with median weight-for-age (−1.09) and median dose (242 mg/m2). Points demonstrate the 
relationship between age and dose which is adjusted for within the multivariable model.
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0.15–0.71; P = 0.003). Associations between age and zidovudine 
exposure varied across the age range (test for nonlinearity P = 0.001). 
Independent of the dose effect, zidovudine exposure was 1.06 (0.48–
1.63) h.mg/L lower and clearance 1.44 (0.67–2.22) L/h.kg higher for 
every year up to 4 years of age (P < 0.001), but there was no associa-
tion for >4 years (exposure P = 0.72, CLF/kg; P = 0.14; Fig. 1B,C). 
Thus, for the same dose in mg/m2, lower clearance meant that young-
est children had higher plasma zidovudine exposure. Exposure was 
0.72 (0.30–1.13) h.mg/L lower and clearance 0.80 (0.24–1.36) L/h.
kg higher for every unit higher weight-for-age (P = 0.001 and P = 
0.005, respectively). Adjusted for these factors, there was no inde-
pendent effect on exposure/clearance of sex (P = 0.56/0.32), height-
for-age (P = 0.57/0.57) or formulation (syrups/tablets; P = 0.75/0.76; 
P = 0.30/0.86 in children under 4 years of age). There was a trend 
toward higher C
max
 in children <4 years [GM = 1.9 mg/L (95% confi-
dence interval: 1.7–2.1)] vs. >4 years [GM = 1.5 mg/L (1.3–1.9) P = 
0.096]. Thirty-seven children had viral load (VL) measured within 4 
weeks of pharmacokinetic sampling day. Thirty-two (86%) had VL 
<80 c/mL; only 1 (3%) had VL >400 c/mL (17,174 c/mL). This 
child had an AUC
0–12h
 of 3.7 h.mg/L.
Thirty-four children had hemoglobin assayed within 1 day 
of the pharmacokinetic sampling. There was marginal evidence 
for 0.31 g/dL lower hemoglobin per 1 h.mg/L higher zidovudine 
AUC
0–12h
 (−0.65 to +0.03; P = 0.07; Fig. 1D).
DISCUSSION
Here, zidovudine exposure in Ugandan children 1–12 years 
of age dosed twice daily according to WHO 2006 weight bands 
was higher than exposure previously reported in adults receiving 
the standard dose of 300 mg zidovudine twice daily.2,11 Exposure 
was also higher (GMs were 2.36 and 1.58 h.mg/L) than in the only 
2 previous pediatric zidovudine pharmacokinetic studies,5,12 which 
used lower doses than our study (Table, Supplemental Digital Con-
tent, http://links.lww.com/INF/B733 and 360 vs. 360–480 mg/m2/d, 
respectively). Subsequent 2010 WHO guidelines1 have further 
increased the recommended zidovudine dose for all children except 
those weighing 15–20 or >30 kg (Table, Supplemental Digital Con-
tent, http://links.lww.com/INF/B733), without new evidence, but 
reflecting concerns that children had often been under dosed with 
antiretrovirals. Thus, exposure in children currently receiving zido-
vudine in Africa is likely to be even higher than observed here.
In addition to the expected association between higher zido-
vudine exposure and mg/m2 dose, we found strong independent 
evidence that higher exposure was associated with lower age in 
children <4 years and with lower weight-for-age. While 1 study 
suggested that zidovudine clearance increased most rapidly during 
the first weeks of life, reaching adult levels at 2 years of age,8 a 
small study in 6 Dutch children5 showed elimination rate increased 
with age between 2 and 14 years, implying further maturation of 
metabolism during childhood. Similarly, we found exposure from 
the same mg/m2 dose decreased in children from 1 to 4 years. An 
alternative explanation might be a greater absorption in younger 
children; although we did not find evidence that liquid versus solid 
formulations might cause this, there was a trend to higher C
max
 in 
younger children. We did not find any association between expo-
sure and age among 19 children who were >4 years of age, but 
moderate-to-large variability may have obscured this.
Data relating zidovudine exposure and toxicity are limited.7,8 
Although only 34 children had paired hemoglobin and pharma-
cokinetic measurements, we found marginal evidence for lower 
hemoglobin values with higher zidovudine exposure. This is simi-
lar to a previous population pharmacokinetic study,8 which found 
mild anemia in 23% of those with average zidovudine concentra-
tion >350 ng/mL (vs. 8% without). However, these children were 
receiving zidovudine as only mono or dual therapy; chronic HIV-
related anemia is common in HIV disease, so the contribution of 
replicating HIV to these findings is unclear. Furthermore, all but 2 
hemoglobin values in our study were in the normal range (1 grade 
1 to 1 grade 2 toxicity). Whether higher exposure increases the risk 
for more severe toxicity over the longer term is unknown.
A study limitation is that we included only Ugandan (East 
African) children, thus limiting generalizability to other populations 
where host genetics may result in different pharmacokinetics. A pop-
ulation pharmacokinetic study including data from 100 children from 
6 pediatric trials, including this study, is ongoing and is expected to 
provide further insight in the pharmacokinetics and potential cofac-
tors that may impact the pediatric pharmacokinetics of zidovudine. 
Another limitation is that the true C
max
 (T
max
 is 0.5 hours)2 could have 
been missed and consequently AUC
0–12h
 might be underestimated. 
Lastly, because of challenges in sampling relatively young children 
over 24 h, we were unable to directly estimate the impact of unequal 
morning and evening dosing in those weighing 20–30 kg.
In summary, zidovudine is a common component of  first-line 
pediatric ART, especially in resource-limited countries and only lim-
ited data are available on the widely applied twice-daily dosing regi-
men. Children dosed following WHO 2010 guidelines, younger chil-
dren and those with low weight-for-age are likely to have even higher 
zidovudine exposure than that observed here and substantially higher 
than previously reported in adults. Our findings suggest that this higher 
exposure could be associated with greater suppression of hemoglobin 
levels within the normal range and probably with no change in efficacy, 
because viral load suppression was already very good using WHO 
2006 dosing. The impact on severe anemia warrants further investiga-
tion, particularly with regards to current WHO 2010 dosing.
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